Novartis's Afinitor flunks breast cancer trial; Supreme Court stays mum on Teva appeal;

@FiercePharma: AbbVie CEO's pay doubles to $18.2M in Abbott pharma spinoff's first solo year. More | Follow @FiercePharma

@TracyStaton: Top-read at FiercePharma: Tokyo hospital exec says Novartis employees deeply involved in leukemia-drug trial. Report | Follow @TracyStaton

@EricPFierce: AmerisourceBergen global expansion continues with $100M deal for a 20% stake in Brazil's Profarma. News | Follow @EricPFierce

@CarlyHFierce: Sanofi reportedly jumps into $12B race for Merck's consumer unit. Story | Follow @CarlyHFierce

>Novartis' ($NVS) breast cancer drug Afinitor missed a secondary endpoint of overall survival in a clinical trial that tested the drug in combination with Pfizer's ($PFE) treatment Aromasin. More

> The Supreme Court once again did not announce whether it would hear Teva's ($TEVA) appeal to reinstate 2015 patents on its multiple sclerosis drug Copaxone. Report

> Pharma wholesaler AmerisourceBergen ($ABC) will invest about $100 million for a minority stake in Brazilian drug distributor Profarma Distribuidora de Produtos Farmacêuticos S.A. More

> IMS Health expects to price its IPO at $18 to $21 per share, valuing the company at up to $6.97 billion. Report

> Bayer was unable to get a tolling ruling nixed in a $100 million sex discrimination suit. More (sub. req.)

> Glenmark Pharmaceuticals has received $4 million as a drug development research fee from Forest Labs ($FRX), bringing the total to $15 million so far from the New York-based company. Story

Medical Device News

@FierceMedDev: The Axonics CEO told FMD that $32.6M in Series A financing took 3 months. "We did not shop the deal," he said. More | Follow @FierceMedDev

@MarkHFierce: Who is the top med tech company in terms of revenue? Report | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Alexza secures $45 million from investors based on U.S. Adasuve sales. Item from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Israeli medical devicemaker Brainsway developed a helmet to treat depression, sees a leap in revenue. Article | Follow @EmilyWFierce

> Stryker finalizes $120M deal with surgical sponge outfit. News

> NeuroPace's neurostimulation epilepsy implant is already making an impact. Item

Biotech News

@FierceBiotech: FDA review slams Novartis's case for beleaguered heart drug serelaxin. More | Follow @FierceBiotech

@JohnCFierce: This is going to be another one of those weak Q1s for biotech VC. I guess the venture crowd is too busy skiing. Summer should be good, though. | Follow @JohnCFierce

@DamianFierce: Biogen cozies up to MIT with a $5.3M drug discovery pact. News | Follow @DamianFierce

@EmilyMFierce: Another gene linked to obesity. Story | Follow @EmilyMFierce

> Merck's new PhIII hep C program may help repair a damaged R&D rep. News

> Seattle startup sets out with $5M, beer molecules and a plan to treat diabetes. Article

Biotech Research News

> Public-private Japanese partnership invests $15M in infectious diseases. Story

> Mushroom-derived compound could stamp out HPV infection. More

> Antianxiety drugs lessen autism symptoms in mice. Item

> Amylin diabetes drug improves learning, memory in Alzheimer's mice. News

> Technique converts stem cells to muscle cells in high volumes. Report

> Knocking out gene reduces fat, extends lifespan in mice. Article

Pharma Manufacturing News

> India cracks down on same Wockhardt plants FDA has banned. More

> GSK adopts Formula One racing mentality to speed Breo inhaler production. Story

> AMRI ratchets manufacturing up further with Cedarburg buyout. News

> FDA approves J&J to make bulk Doxil at closed Ben Venue plant. Report

> Hospira CEO gets nearly $10M for steering drugmaker through issues. Article

> AmerisourceBergen expands in Brazil with $100M deal. Item

And Finally... Marijuana can help ease certain MS symptoms in ways other alternative remedies can't, according to a report by U.S. neurologists. More

Suggested Articles

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.

Dupixent's number-one position in the eczema market will be tough to maintain as two dozen rivals line up to unseat it, Cantor Fitzgerald warns.